Multicenter Study for External Validation of the TB-NET Score (TB-NET)
Multicentric Study for External Validation of the TB-NET Score
This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or lung carcinoids. The primary objective is to validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the evaluation of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and the potential additional prognostic value of tumor growth rate (TGR).
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This is a retrospective, observational, multicenter study designed to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated neuroendocrine tumors.
Eligible patients will include adults with histologically confirmed advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or typical or atypical lung carcinoids who have received systemic therapy. GEP-NETs may be grade 1, 2, or 3, provided that well-differentiated morphology is confirmed. Patients with poorly differentiated neuroendocrine carcinomas will be excluded.
The primary objective is to externally validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the assessment of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and evaluation of whether tumor growth rate (TGR) provides additional prognostic information for PFS.
A minimum of 200 patients is planned, with no predefined maximum sample size. Clinical, pathological, radiological, treatment, and outcome data will be retrospectively collected by participating centers and entered into a centrally coordinated electronic data capture system. Statistical analyses will be performed centrally by the Gastrointestinal Tumors Unit at Fundación Jiménez Díaz.
Only pseudonymized data will be shared for the purposes of the study. Data transfers between participating centers and the Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD) will be governed by appropriate data transfer agreements when required. The study has received approval from the Research Ethics Committee of Fundación Jiménez Díaz.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Angela Lamarca, MD, PhD
- Telefonnummer: 3146 +34 915504800
- E-Mail: angela.lamarca@quironsalud.es
Studieren Sie die Kontaktsicherung
- Name: Diego Fernández, MD
- Telefonnummer: +34 636284882
- E-Mail: diego.fernandezr@quironsalud.es
Studienorte
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 01308-050
- Rekrutierung
- Hospital Sírio-Libanês
-
Kontakt:
- Regis Franca, MD
- Telefonnummer: +55 11 3394-0200
- E-Mail: regisfranca@gmail.com
-
-
-
-
Bavaria
-
Erlangen, Bavaria, Deutschland, 91054
- Rekrutierung
- Universitätsklinikum Erlangen
-
Kontakt:
- Marianne Pavel, MD
- Telefonnummer: +49 9131 85-0
- E-Mail: marianne.pavel@uk-erlangen.de
-
-
-
-
-
Clichy, Frankreich, 92110
- Rekrutierung
- Hôpital Beaujon
-
Kontakt:
- Maxime Ronot, MD, PhD
- Telefonnummer: +33 1 40 87 50 00
- E-Mail: maxime.ronot@gmail.com
-
-
-
-
Lombardy
-
Milan, Lombardy, Italien, 20132
- Rekrutierung
- IRCCS Ospedale San Raffaele
-
Kontakt:
- Massimo Falconi, MD
- Telefonnummer: +39 02 26431
- E-Mail: falconi.massimo@hsr.it
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-688
- Rekrutierung
- University Hospital in Kraków
-
Kontakt:
- Marta Opalinska, MD, PhD
- Telefonnummer: +48 12 400 10 00
- E-Mail: mkal@vp.pl
-
-
-
-
Skåne County
-
Malmö, Skåne County, Schweden, 214 28
- Rekrutierung
- Skåne University Hospital
-
Kontakt:
- Carl Fredrik Warfvinge, MD
- Telefonnummer: +46 40331000
- E-Mail: carl_fredrik.warfvinge@med.lu.se
-
-
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Rekrutierung
- Hospital Universitario Marqués de Valdecilla
-
Kontakt:
- Carlos Lopez, MD
- E-Mail: clopez@humv.es
-
-
Madrid
-
Madrid, Madrid, Spanien, 28040
- Rekrutierung
- Hospital Universitario Fundación Jiménez Díaz
-
Kontakt:
- Diego Fernández, MD
- Telefonnummer: +34 636284882
- E-Mail: diego.fernandezr@quironsalud.es
-
-
-
-
Ankara
-
Ankara, Ankara, Türkei (türkiye), 06080
- Rekrutierung
- Hacettepe University Hospitals
-
Kontakt:
- Murat Tuncel, MD
- Telefonnummer: +90 3123055000
- E-Mail: murat.tuncel@hacettepe.edu.tr
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Dana-Farber Cancer Institute
-
Kontakt:
- Jennifer Chan, MD
- Telefonnummer: 617-632-3000
- E-Mail: jennifer_chan@dfci.harvard.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.
Beschreibung
Inclusion Criteria:
- Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.
- Grade 1, 2 or 3 if well-differentiated morphology for GEP-NETs. Typical or Atypical Lung Carcinoids.
- At least one target lesion.
Exclusion Criteria:
- Patients with Neuroendocrine Carcinomas.
- Patients with no target lesions (according to RECIST 1.1 criteria).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: RETROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Patients With Advanced Well-Differentiated NETs
Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-Free Survival (PFS)
Zeitfenster: From treatment initiation until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 120 months.
|
Progression-free survival, defined as the time from treatment initiation to documented disease progression. Patients without documented progression at the end of follow-up will be censored at the date of the last follow-up without progression. |
From treatment initiation until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 120 months.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate (ORR)
Zeitfenster: From treatment initiation until disease progression or the last tumor response assessment, assessed up to 120 months.
|
Response rate defined by RECIST 1.1 |
From treatment initiation until disease progression or the last tumor response assessment, assessed up to 120 months.
|
|
Overall Survival (OS)
Zeitfenster: From treatment initiation until death from any cause or last follow-up, assessed up to 120 months.
|
The time from treatment initiation to death; patients alive at the end of follow up will be censored at the time of last follow up. |
From treatment initiation until death from any cause or last follow-up, assessed up to 120 months.
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Grade 3-4 Adverse Events According to CTCAE
Zeitfenster: From treatment initiation until treatment discontinuation or the last available safety assessment, assessed up to 120 months.
|
The proportion of patients experiencing at least one Grade 3 or 4 adverse event during treatment, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE). Grade 3 adverse events are defined as severe, and Grade 4 adverse events as life-threatening. |
From treatment initiation until treatment discontinuation or the last available safety assessment, assessed up to 120 months.
|
|
Correlation of Chromogranin A, 5-HIAA, and Neuron-Specific Enolase Levels With TB-NET Score
Zeitfenster: At baseline, prior to treatment initiation.
|
The association between baseline biochemical marker levels, including chromogranin A (CgA), 5-hydroxyindoleacetic acid (5-HIAA), and neuron-specific enolase (NSE), and tumor burden assessed using the TB-NET Score will be evaluated. Correlations will be analyzed separately for each biomarker using appropriate statistical methods. |
At baseline, prior to treatment initiation.
|
|
Percentage of Patients With Positive Baseline 18F-FDG PET/CT According to TB-NET Score Risk Group
Zeitfenster: At baseline, prior to treatment initiation.
|
The percentage of patients with positive baseline fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) will be calculated separately for the low-risk (TB-NET Score 1-2) and high-risk (TB-NET Score ≥3) groups. Imaging positivity will be assessed as a binary variable (positive versus negative) based on the imaging report. Only patients with available baseline 18F-FDG PET/CT results will be included. Unit of Measure: Percentage of patients. |
At baseline, prior to treatment initiation.
|
|
Incremental Prognostic Value of Tumor Growth Rate at 3 and 6 Months for Progression-Free Survival
Zeitfenster: TGR assessed at 3 and 6 months after treatment initiation; subsequent PFS assessed from each landmark until disease progression or death from any cause, whichever occurs first, up to 120 months after treatment initiation.
|
The incremental prognostic value of tumor growth rate (TGR), assessed at 3 and 6 months after treatment initiation, will be evaluated for progression-free survival (PFS). TGR will be calculated using serial radiological tumor measurements and expressed as percentage tumor growth per month. Separate landmark analyses at 3 and 6 months will assess the association between TGR and subsequent PFS using Cox proportional hazards regression models, comparing the TB-NET Score alone with the TB-NET Score plus TGR. |
TGR assessed at 3 and 6 months after treatment initiation; subsequent PFS assessed from each landmark until disease progression or death from any cause, whichever occurs first, up to 120 months after treatment initiation.
|
|
Percentage of Patients With Positive Baseline 68Ga-SSTR PET/CT According to TB-NET Score Risk Group
Zeitfenster: At baseline, prior to treatment initiation.
|
The percentage of patients with positive baseline gallium-68-labeled somatostatin receptor positron emission tomography/computed tomography (68Ga-SSTR PET/CT) will be calculated separately for the low-risk (TB-NET Score 1-2) and high-risk (TB-NET Score ≥3) groups. Imaging positivity will be assessed as a binary variable (positive versus negative) based on the imaging report. Only patients with available baseline 68Ga-SSTR PET/CT results will be included. Unit of Measure: Percentage of patients. |
At baseline, prior to treatment initiation.
|
|
Percentage of Patients With Positive Baseline Somatostatin Receptor Scintigraphy According to TB-NET Score Risk Group
Zeitfenster: At baseline, prior to treatment initiation.
|
The percentage of patients with positive baseline somatostatin receptor scintigraphy (OctreoScan) will be calculated separately for the low-risk (TB-NET Score 1-2) and high-risk (TB-NET Score ≥3) groups. Imaging positivity will be assessed as a binary variable (positive versus negative) based on the imaging report. Only patients with available baseline OctreoScan results will be included. Unit of Measure: Percentage of patients. |
At baseline, prior to treatment initiation.
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Angela Lamarca, MD, PhD, Hospital Universitario Fundación Jiménez Díaz
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- EO016-26_FJD
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .